Sanofi SA's decision to hand back rights added another chapter to the saga of Mannkind Corp. with inhaled insulin Afrezza, but the hard-hit biotech firm's chief financial officer, Matthew Pfeffer, said the quit is "not the end of the line for Afrezza or Mannkind, by any means."